Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Sunshine Biopharma (SBFM) EBIAT (2016 - 2025)

Sunshine Biopharma's EBIAT history spans 14 years, with the latest figure at -$2.1 million for Q4 2025.

  • For Q4 2025, EBIAT rose 0.8% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$6.0 million, down 16.39%, while the annual FY2025 figure was -$6.0 million, 16.39% down from the prior year.
  • EBIAT reached -$2.1 million in Q4 2025 per SBFM's latest filing, down from -$883820.0 in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $667116.0 in Q4 2021 to a low of -$23.5 million in Q4 2022.
  • Average EBIAT over 5 years is -$2.7 million, with a median of -$1.3 million recorded in 2023.
  • The largest YoY upside for EBIAT was 161.55% in 2021 against a maximum downside of 6461.84% in 2021.
  • A 5-year view of EBIAT shows it stood at $667116.0 in 2021, then plummeted by 3624.47% to -$23.5 million in 2022, then surged by 94.68% to -$1.3 million in 2023, then tumbled by 72.65% to -$2.2 million in 2024, then grew by 0.8% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EBIAT are -$2.1 million (Q4 2025), -$883820.0 (Q3 2025), and -$1.8 million (Q2 2025).